title: Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane.
abstract: Fibrillar protein deposits (amyloid) in the pancreatic islets of Langerhans are thought to be involved in death of the insulin-producing islet beta cells in type 2 diabetes mellitus. It has been suggested that the mechanism of this beta cell death involves membrane disruption by human islet amyloid polypeptide (hIAPP), the major constituent of islet amyloid. However, the molecular mechanism of hIAPP-induced membrane disruption is not known. Here, we propose a hypothesis that growth of hIAPP fibrils at the membrane causes membrane damage. We studied the kinetics of hIAPP-induced membrane damage in relation to hIAPP fibril growth and found that the kinetic profile of hIAPP-induced membrane damage is characterized by a lag phase and a sigmoidal transition, which matches the kinetic profile of hIAPP fibril growth. The observation that seeding accelerates membrane damage supports the hypothesis. In addition, variables that are well known to affect hIAPP fibril formation, i.e., the presence of a fibril formation inhibitor, hIAPP concentration, and lipid composition, were found to have the same effect on hIAPP-induced membrane damage. Furthermore, electron microscopy analysis showed that hIAPP fibrils line the surface of distorted phospholipid vesicles, in agreement with the notion that hIAPP fibril growth at the membrane and membrane damage are physically connected. Together, these observations point toward a mechanism in which growth of hIAPP fibrils, rather than a particular hIAPP species, is responsible for the observed membrane damage. This hypothesis provides an additional mechanism next to the previously proposed role of oligomers as the main cytotoxic species of amyloidogenic proteins.
authors.affiliation: Department of Metabolic and Endocrine Diseases, Division of Biomedical Genetics, University Medical Center Utrecht, P. O. Box 85090, 3508 AB Utrecht, The Netherlands. m.engel@leeds.ac.uk
authors.forename: Maarten F M
authors.initials: MF
authors.lastname: Engel
authors.forename: Lucie
authors.initials: L
authors.lastname: Khemtémourian
authors.forename: Cécile C
authors.initials: CC
authors.lastname: Kleijer
authors.forename: Hans J D
authors.initials: HJ
authors.lastname: Meeldijk
authors.forename: Jet
authors.initials: J
authors.lastname: Jacobs
authors.forename: Arie J
authors.initials: AJ
authors.lastname: Verkleij
authors.forename: Ben
authors.initials: B
authors.lastname: de Kruijff
authors.forename: J Antoinette
authors.initials: JA
authors.lastname: Killian
authors.forename: Jo W M
authors.initials: JW
authors.lastname: Höppener
mesh_terms: D000682:Amyloid / Q000378:metabolism*; D000818:Animals; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure*; D003924:Diabetes Mellitus, Type 2 / Q000473:pathology*; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D050417:Insulin-Secreting Cells / Q000378:metabolism / Q000648:ultrastructure*; D058228:Islet Amyloid Polypeptide; D007700:Kinetics; D051379:Mice; D008854:Microscopy, Electron
chemical_list: D000682:Amyloid; D007328:Insulin; D058228:Islet Amyloid Polypeptide